Clinical Study of YQ1 Plus Cisplatin-based Chemotherapy in Advanced NSCLC EGFR Wild Type

Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) that is advanced/metastatic (stage IIIB/IV), EGFR/ALK wild type. * Subjects who plan to receive cisplatin-based chemotherapy. * Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document Exclusion Criteria: * ECOG performance status \>= 3 * WBC =\< 4,000 cells/μl, ANC =\< 1,500/mcL, Platelets =\< 100,000/mcL , Hemoglobin =\< 9 g/dL, * Total bilirubin \>= 1.5 x upper limit of normal (ULN), AST \>= 1.5x ULN, ALT \>= 2.5 x ULN, Creatinine \>= 1.5x ULN * Current uncontrolled cardiac disease such as angina or myocardial infarction, congestive heart failure. * Chronic or current Inflammatory Bowel Disease, post-surgery of intestine, Lynch syndrome, FAP, Peutz-Jegher. * History of allergic reactions cisplatin * Pregnant women are excluded; breastfeeding should be discontinued prior to study entry. * Received any other clinical trail at the same time. * Current dementia or other cognitive disorders.